Catalent Expands Partnership with Johnson & Johnson to Significantly Increase Capacity for Sterile Manufacturing and Packaging of COVID-19 Vaccine in Italy
Share Article
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced an expanded partnership with Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc., two of the Janssen Pharmaceutical Companies of Johnson & Johnson, whereby Catalent Biologics will significantly increase the manufacturing capacity for large-scale commercial supply of Janssen’s COVID-19 vaccine at Catalent’s manufacturing facility in Anagni, Italy, including vial-filling, inspection, labeling, and packaging services.
By Reuters Staff
1 Min Read
March 17 (Reuters) - Contract manufacturer Catalent said on Wednesday it was expanding its partnership with Johnson & Johnson to raise the manufacturing capacity at its plant in Anagni, Italy for large-scale supply of J&J’s COVID-19 vaccine.
Reporting by Manojna Maddipatla in Bengaluru; Editing by Anil D’Silva
Catalent plans to expand production of J&J COVID-19 vaccine in Italy: WSJ reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
Catalent plans to expand production of J&J COVID-19 vaccine in Italy: WSJ metro.us - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from metro.us Daily Mail and Mail on Sunday newspapers.